

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

GUIDANCE EXECUTIVE (GE)

Consideration of consultation responses on review proposal

Review of TA115: Naltrexone for the management of opioid dependence

This guidance was issued in January 2007 with a review date of March 2010.

Background

At the GE meeting on 21 August 2010 it was agreed we would consult on the review plans for this guidance. A four week consultation has been conducted with consultees and commentators and the responses are presented below.

Proposal put to consultees:	A review of the guidance should be transferred to the 'static guidance list'.
------------------------------------	---

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

Recommendation post consultation:	A review of the guidance should be transferred to the 'static guidance list'.
--	---

Respondent	Response to proposal	Details	Comment from Technology Appraisal
British Association for	No objection		Comment noted.

Psychopharmacology			
Bristol-Myers Squibb	Agree		Comment noted.
Medicines and Healthcare products Regulatory Agency (MHRA)	No comment		Noted.
NHS Quality Improvement Scotland	No comment		Noted.
National Treatment Agency for Substance Misuse	Agree	<i>“the NTA would like to alert NICE that it has commissioned, and is currently discussing terms of reference for a review of current prescribing practice in the treatment of opioid dependence in England.”</i>	Comment noted. Naltrexone is indicated in formerly opioid-dependent patients. No actions requested.
Royal College of Nursing	No objection	<i>“ It has [...] been that stated that a new injectable depot of naltrexone was licensed but there does not seem to be much information on it being prescribed. It was suggested that this might be worth investigating.”</i>	Comment noted. Depot naltrexone is not licensed. No actions requested. Please note that an appraisal on the static list can be reviewed if new information on the licensing of new formulations comes to light, which may materially affect the recommendations contained within an appraisal on the static list.

No response received from:

Consultees	Commentators (no right to submit or appeal)
<p>Manufacturers/sponsors</p> <ul style="list-style-type: none"> • AOP Orphan Pharmaceuticals <p>Patient/carer groups</p> <ul style="list-style-type: none"> • Addaction • Adfam • Afiya Trust • Alliance • Black Health Agency • Chinese National Healthy Living Centre • Counsel and Care • Equalities National Council • Families Anonymous UK • Lifeline • Muslim Council of Britain • Muslim Health Network • Rehabilitation for Addicted Prisoners Trust (RAPt) • Release • South Asian Health Foundation • Specialised Healthcare Alliance • Turning Point <p>Professional groups</p> <ul style="list-style-type: none"> • Addiction Recovery Foundation • Association of Nurses in Substance Abuse • British Association for Services to the Elderly • British Geriatrics Society • European Association for the Treatment of Addiction UK • Federation of Drug and Alcohol Professionals 	<p>General</p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • HM Prison Service • National Association of Primary Care • National Treatment Agency for Substance Misuse (NTA) • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Public Health Wales NHS Trust • Scottish Medicines Consortium <p>Comparator manufacturers</p> <ul style="list-style-type: none"> • none <p>Relevant research groups</p> <ul style="list-style-type: none"> • Action on Addiction • Centre for Research on Drugs and Health Behaviour (Imperial College) • Department of Addictive Behaviour and Psychological Medicine (St George's Hospital Medical School) • DrugScope • Independent Drug Monitoring Unit (IDMU) • MRC Clinical Trials Unit • National Addiction Centre (Institute of Psychiatry)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • National Drug Prevention Alliance • National Pharmaceutical Association • Pharmaceutical Services Negotiating Committee • Royal College of General Practitioners • Royal College of Nursing • Royal College of Physicians • Royal College of Psychiatrists (Addictions Faculty) • Royal Pharmaceutical Society • Royal Society of Medicine • Specialist Clinical Addiction Network (SCAN) • Substance Misuse Management in General Practice (SMMGP) • United Kingdom Clinical Pharmacy Association • UK Harm Reduction Alliance <p>Others</p> <ul style="list-style-type: none"> • Department of Health • NHS Brighton and Hove • NHS Bristol • Welsh Assembly Government 	<ul style="list-style-type: none"> • National Institute for Health Research • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People • Society for the Study of Addiction <p>Assessment Group</p> <ul style="list-style-type: none"> • National Institute for Health Research (NIHR) Health Technology Assessment Programme <p>Associated Guideline Groups</p> <ul style="list-style-type: none"> • National Collaborating Centre for Mental Health <p>Associated Public Health Groups</p> <ul style="list-style-type: none"> • none

GE paper sign-off: Elisabeth George, 06 10 10

Contributors to this paper:

Information Specialist: Tom Hudson

Technical Lead: Helen Starkie

Technical Adviser: Bhash Naidoo

Project Manager: Andrew Harding